FrancophonIA/ELRC3.0 huggingface dataset:
English: Active substance: Meloxicam 0.5 mg (equivalent to 0.017 mg per drop)
Croatian: Meloksikam 0,5 mg (odgovara 0,017 mg po kapi)
English: Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound.
Croatian: Meloksikam se pretežno nađe u plazmi a također se uglavnom izlučuje preko žuči, dok mokraća sadrži samo tragove ishodišnog spoja.
English: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on day 1 (pre-surgery).
Croatian: Početna doza je jedna oralna doza od 0,2 mg meloksikama/kg tjelesne mase na 1. dan (prije zahvata).
English: PACKAGE LEAFLET: Metacam 0.5 mg/ml oral suspension for dogs
Croatian: UPUTA O VMP: Metacam 0,5 mg/ml oralna suspenzija za pse
English: Metacam 0.5 mg/ml oral suspension for dogs Meloxicam
Croatian: Metacam 0,5 mg/ml oralna suspenzija za pse Meloksikam
English: Push down and unscrew bottle top.
Croatian: Gurnite zatvarač bočice prema dolje i odvrnite ga.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals Accidental self-injection may give rise to pain.
Croatian: Posebne mjere predostrožnosti koje mora poduzeti osoba koja primjenjuje veterinarsko-medicinski proizvod na životinjama
English: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.
Croatian: Jedna subkutana injekcija u dozi od 0,3 mg meloksikama/kg tjelesne mase (tj. 0,06 ml/10 kg tjelesne mase) prije kirurškog zahvata, primjerice u vrijeme uvođenja u anesteziju.
English: Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Meglumine
Croatian: 6.1 Popis pomoćnih tvari etanol poloksamer 188 makrogol 300 glicin dinatrijev edetat natrijev hidroksid (za prilagodbu pH) hidroklorna kiselina (za prilagodbu pH) meglumin voda za injekcije
English: EU/2/97/004/035 1 x 20 ml EU/2/97/004/037 1 x 50 ml EU/2/97/004/001 1 x 100 ml EU/2/97/004/036 12 x 20 ml EU/2/97/004/038 12 x 50 ml EU/2/97/004/010 12 x 100 ml
Croatian: EU/2/97/004/035 20 ml EU/2/97/004/037 50 ml EU/2/97/004/001 100 ml EU/2/97/004/036 12 x 20 ml EU/2/97/004/038 12 x 50 ml EU/2/97/004/010 12 x 100 ml
English: meat and offal: 5 days
Croatian: meso i jestive iznutrice: 5 dana
English: IV injection.
Croatian: Jedna i.v.injekcija.
English: Metacam 40 mg/ml injection for cattle and horses meloxicam
Croatian: Metacam 40 mg/ml injekcija za goveda i konje meloksikam
English: SC or IV injection
Croatian: i.v. injekcija
English: Active substance: Meloxicam 0.5 mg (equivalent to 0.02 mg per drop)
Croatian: Meloksikam 0,5 mg (odgovara 0,02 mg po kapi)
English: Active substance: Meloxicam 1.5 mg (equivalent to 0.05 mg per drop)
Croatian: Meloksikam 1,5 mg (odgovara 0,05 mg po kapi)
English: Vials, 100 ml and 250 ml
Croatian: Boca, 100 ml i 250 ml
English: THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"
Croatian: 11. POSEBNE MJERE PRI ČUVANJU Držati izvan pogleda i dosega djece.
English: Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Croatian: Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu letargije i zatajenja bubrega.
English: Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.
Croatian: Ublažavanje upale i bolova u akutnim i kroničnim mišićno-koštanim poremećajima u konja.
English: subcutaneous use, intravenous use.
Croatian: potkožno, u venu.
English: Vial, 50 ml and 20 ml
Croatian: Bočica, 50 ml i 20 ml
English: Disodium edetate Sodium hydroxide Hydrochloric acid Meglumine Water for injections
Croatian: 6.1 Popis pomoćnih tvari etanol poloksamer 188 natrijev klorid glicin natrijev hidroksid glikofurol meglumin voda za injekcije
English: Metacam 40 mg/ml solution for injection for cattle and horses meloxicam
Croatian: Metacam 40 mg/ml otopina za injekcije za goveda i konje meloksikam
English: Marketing authorisation holder: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY
Croatian: Nositelj odobrenja za stavljanje u promet: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein NJEMAČKA
English: EU/2/97/004/053 12 x 100 ml
Croatian: EU/2/97/004/051 100 ml. EU/2/97/004/053 12 x 100 ml
English: Name and address of the manufacturers responsible for batch release
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornih za puštanje serije u promet Otopina za injekcije
English: Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.
Croatian: Početak liječenja čini jednokratna doza od 0,2 mg meloksikama/kg tjelesne mase primijenjena prvog dana.
English: Attach the dosing syringe to the drop dispenser of the bottle by gently pushing.
Croatian: Laganim pritiskom pričvrstite dozirnu štrcaljku na kapaljku bočice.
English: Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.1 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.
Croatian: Jedna subkutana injekcija u dozi od 0,2 mg meloksikama/kg tjelesne mase (tj. 0,1 ml/kg tjelesne mase) prije kirurškog zahvata, primjerice u vrijeme uvođenja u anesteziju.
English: Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg).
Croatian: jedna primjena od 0,2 mg meloksikama/kg tjelesne mase (tj. 0,4 ml/10 kg).
English: Meat and offal: 15 days; Milk: 5 days
Croatian: Meso i jestive iznutrice: 15 dana; mlijeko: 5 dana
English: 3 drops/kg body weight.
Croatian: 6 kapi /kg tjelesne mase.
English: Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by intravenous E. coli endotoxin administration in pigs.
Croatian: Meloksikam ima također svojstva protiv endotoksičnosti, jer se pokazalo da koči proizvodnju tromboksana B2 potaknutog unosom endotoksina E. coli u svinja.
English: Vial, 20 ml and 50 ml
Croatian: Bočica, 20 ml i 50 ml
English: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day.
Croatian: Početak liječenja čini jednokratna oralna doza od 0,2 mg meloksikama/kg tjelesne mase primijenjena prvog dana.
English: Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day.
Croatian: Početak liječenja čini jednokratna oralna doza od 0,1 mg meloksikama/kg tjelesne mase primijenjena prvog dana.
English: Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e. 1.25 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
Croatian: Jedna supkutano ili intravenska injekcija u dozi od 0,5 mg meloksikama/kg tjelesne mase (tj. 1,25 ml/100 kg tjelesne mase) u kombinaciji s antibiotskom terapijom ili peroralnom rehidracijskom terapijom, kako je odgovarajuće.
English: Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10.0 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
Croatian: Jedna subkutana ili intravenska injekcija u dozi od 0,5 mg meloksikama/kg tjelesne mase (tj. 10,0 ml/100 kg tjelesne mase) u kombinaciji s antibiotskom terapijom ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
English: Single subcutaneous injection of 0.2 mg meloxicam/kg body weight (i.e. 0.1 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.
Croatian: Jedna subkutana primjena od 0,2 mg meloksikama/kg tjelesne mase (tj. 0,1 ml/10 kg tjelesne mase) prije kirurškog zahvata, primjerice u vrijeme uvođenja u anesteziju.
English: Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e. 10.0 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
Croatian: Jedna subkutana ili intravenska injekcija u dozi od 0,5 mg meloksikama/kg tjelesne mase (tj. 10,0 ml/100 kg tjelesne mase) u kombinaciji s terapijom antibioticima ili oralnom rehidracijskom terapijom, kako je odgovarajuće.
English: Marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY
Croatian: Nositelj odobrenja za stavljanje u promet Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein NJEMAČKA
English: In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
Croatian: U slučaju da se nehotice samo injiciranja, odmah potražiti pomoć liječnika i pokažite mu ovu uputu o VMP ili etiketu.
English: Disodium edetate
Croatian: SAŽETAK OPISA SVOJSTAVA
English: In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Croatian: U slučaju da se nehotice samo injicira, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
English: 6 drops/kg body weight
Croatian: 2 kapi /kg tjelesne mase
English: Do not use in guinea pigs less than 4 weeks of age.
Croatian: Ne primjenjivati u zamorčadi mlađe od 4 tjedna.
English: Active substance: Meloxicam 15 mg
Croatian: Meloksikam 15 mg
English: Active substance: Meloxicam 2 mg
Croatian: Meloksikam 2 mg
English: Vial, 10 ml and 20 ml
Croatian: Bočica, 10 ml i 20 ml
English: In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the carton to the physician.
Croatian: U slučaju da se nehotice proguta, odmah potražiti pomoć liječnika i pokažite mu ovu uputu o VMP ili kutiju.
English: Withdrawal period: Meat and offal: 3 days.
Croatian: Karencija(e): Meso i jestive iznutrice: 3 dana.
English: Withdrawal period: Cattle:
Croatian: NAČIN I PUT(EVI) PRIMJENE Goveda:
English: These side effects usually disappear within one to two days without treatment.
Croatian: Ove nuspojave najčešće nestaju u roku od jednog ili dva dana bez liječenja.
English: The full EPAR for Optaflu can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Optaflu nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The vaccine's effectiveness was assessed in one main study involving 2,654 adults, around half of whom were elderly (over 60 years of age).
Croatian: Djelotvornost cjepiva procijenjena je u jednom glavnom ispitivanju koje je obuhvatilo 2 654 odraslih osoba, od kojih je otprilike polovica bila starije dobi (stariji od 60 godina).
English: The use of the vaccine should be based on official
Croatian: Uporaba cjepiva mora se temeljiti na službenim preporukama.
English: People who have a fever or an acute (short-lived) infection should not receive the vaccine until they have recovered.
Croatian: Osobe koje imaju vrućicu ili akutnu (kratkotrajnu) upalu ne smiju primiti cjepivo sve dok se ne oporave.
English: What measures are being taken to ensure the safe and effective use of Optaflu?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Optaflu?
English: This is a summary of the European public assessment report (EPAR) for Optaflu.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Optaflu.
English: Other information about Optaflu
Croatian: Ostale informacije o lijeku Optaflu
English: influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
Croatian: Optaflu cjepivo protiv influence (površinski antigen, inaktivirano, pripremljeno iz staničnih kultura)
English: The most common side effects with Optaflu (seen in more than 1 patient in 10) are headache, reddening of the skin, muscle pain, pain at the site of injection, malaise (feeling unwell) and fatigue (tiredness).
Croatian: Najčešće nuspojave lijeka Optaflu (mogu se javiti u više od 1 na 10 osoba) su glavobolja, crvenilo kože, bol u mišićima, bol na mjestu injekcije, malaksalost (osjećaj slabosti) te iscrpljenost (umor).
English: Optaflu is a vaccine.
Croatian: Optaflu je cjepivo.
English: The antibodies will then help to protect against the disease caused by these strains of the flu virus.
Croatian: Protutijela zatim pomažu u zaštiti od bolesti uzrokovane tim sojevima virusa gripe.
English: In the future, the immune system will be able to produce antibodies more quickly when it is exposed to any of these virus strains.
Croatian: Imunosni sustav će zatim u budućnosti moći brže stvarati protutijela nakon izloženosti bilo kojem od ovih sojeva virusa.
English: Optaflu is given as one injection of 0.5 ml into the muscle at the top of the arm.
Croatian: Optaflu se daje kao jedna injekcija od 0,5 ml u mišić nadlaktice.
English: For more information about treatment with Optaflu, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Optaflu pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Optaflu is used to vaccinate adults against flu, especially those who are at an increased risk of developing complications from the disease.
Croatian: Optaflu se koristi za cijepljenje odraslih osoba protiv gripe, posebice onih koji su izloženi riziku od razvijanja komplikacija bolesti.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Optaflu.
English: Optaflu contains fragments from the surface of three different strains of flu virus.
Croatian: Optaflu sadrži fragmente iz površine triju različitih sojeva virusa gripe.
English: A risk management plan has been developed to ensure that Optaflu is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Optaflu.
English: Optaflu is a vaccine, which is available as a suspension for injection in a pre-filled syringe.
Croatian: Optaflu je cjepivo koje je dostupno kao suspenzija za injekciju u napunjenoj štrcaljki.
English: Each year, the World Health Organization (WHO) makes recommendations on which flu strains should be included in vaccines for the upcoming flu season.
Croatian: Svake godine Svjetska zdravstvena organizacija (SZO) preporuča koji se sojevi gripe moraju uključiti u cjepiva za nadolazeću sezonu gripe.
English: The ability of Optaflu to trigger the production of antibodies (immunogenicity) was first assessed using a formulation of the vaccine that included the virus strains expected to cause flu in the 2004/2005 season.
Croatian: Sposobnost cjepiva Optaflu da potakne proizvodnju protutijela (imunogenost) prvi je put procijenjena primjenom formulacije cjepiva koja je uključivala sojeve virusa za koje se očekivalo da će uzrokovati gripu u sezoni 2004./2005.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Optaflu, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Optaflu nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: What is the risk associated with Optaflu?
Croatian: Koji su rizici povezani s lijekom Optaflu?
English: The two vaccines were similar in triggering the production of antibodies, both in adults 60 years of age and below, and in the elderly.
Croatian: Dva su cjepiva polučila slične rezultate u poticanju stvaranja protutijela, kako u odraslih osoba u dobi od 60 godina i mlađih tako i u starijih osoba.
English: The CHMP decided that Optaflu's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: CHMP je odlučio da koristi od lijeka Optaflu nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: A/California/7/2009 (H1N1)pdm09-like strain; A/Switzerland/9715293/2013 (H3N2)-like strain; and
Croatian: Cjepivo sadrži inaktivirane „površinske antigene” iz tri različita soja (tipa) virusa influence (gripe): soj sličan A/California/7/2009 (H1N1)pdm09, soj sličan A/Switzerland/9715293/2013 (H3N2) i soj sličan B/Phuket/3073/2013.
English: Optaflu contains fragments (surface antigens) of the virus strains that are expected to cause flu in the upcoming season, according to the recommendations from the WHO for the northern hemisphere and from the European Union (EU), need to be included in Optaflu before the vaccine can be used.
Croatian: Fragmenti sojeva virusa (površinski antigeni) za koje se očekuje da će prouzročiti gripu u nadolazećoj sezoni, u skladu s preporukama SZO-a za sjevernu hemisferu kao i preporukama Europske unije (EU), moraju biti dodani cjepivu Optaflu prije korištenja.
English: In the original main study, both Optaflu and the comparator vaccine brought about adequate levels of antibodies for protection against all three flu strains, as defined in criteria laid down by the CHMP for flu vaccines.
Croatian: U izvornom glavnom ispitivanju, Optaflu i usporedno cjepivo rezultirali su primjerenim razinama protutijela za zaštitu protiv tri soja gripe, kako je definirano u kriterijima koje je utvrdio CHMP za cjepiva protiv gripe.
English: The viruses used to obtain the surface antigen that are included in Optaflu are grown in mammalian cells, unlike those used for other flu vaccines, which are grown in hen's eggs.
Croatian: Virusi korišteni kako bi se dobili površinski antigeni koji su uključeni u cjepivo Optaflu uzgajaju se u stanicama sisavaca, za razliku od onih koji se koriste u drugim cjepivima protiv gripe, koji se uzgajaju u kokošjim jajima.
English: The study compared the ability of the two vaccines to trigger the production of antibodies (immunogenicity), by comparing antibody levels before injection
Croatian: U ispitivanjima je uspoređena sposobnost dvaju cjepiva da aktiviraju stvaranje protutijela (imunogenost), uspoređujući razine protutijela prije injekcije i tri tjedna nakon injekcije.
English: Later seasonal formulations of Optaflu have been shown to bring about similar antibody responses against the three flu strains included in the vaccine to those seen in the main study.
Croatian: Kasnije sezonske formulacije lijeka Optaflu potaknule su slične odgovore protutijela protiv sva tri soja gripe uključena u cjepivo kao u glavnim ispitivanjima.
English: What benefit has Optaflu shown during the studies?
Croatian: Koje su koristi lijeka Optaflu utvrđene u ispitivanjima?
English: The effects of Optaflu were compared to those of a similar flu vaccine that was made in eggs.
Croatian: Djelovanje cjepiva Optaflu uspoređeno je s djelovanjem sličnih cjepiva protiv gripe koja su proizvedena u jajima.
English: The European Commission granted a marketing authorisation valid throughout the European Union for
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Optaflu na snazi u Europskoj uniji od 1. lipnja 2007.
English: For the full list of all side effects reported with Optaflu, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Optaflu potražite u uputi o lijeku.
English: This authorisation was based on the authorisation granted to Competat on 28 July 2006 (‘informed consent').
Croatian: Odobrenje se temeljilo na odobrenju danom za lijek Competact 28. srpnja 2006.(„informirani pristanak”).
English: These side effects are very common but disappear on their own in most cases.
Croatian: Te su nuspojave vrlo česte, međutim u većini slučajeva nestaju same od sebe.
English: The full EPAR for Glubrava can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Glubrava nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The studies lasted from four months to two years and involved 1,305 patients who took the combination.
Croatian: Ta su ispitivanja trajala od četiri mjeseca do dvije godine i uključivala su 1 305 bolesnika koji su uzimali tu kombinaciju lijekova.
English: Pioglitazone / metformin hydrochloride
Croatian: Glubrava pioglitazon / metformin hidroklorid
English: Elderly patients should have their kidney function monitored regularly.
Croatian: Bolesnicima starije dobi mora se redovito pratiti funkcija rada bubrega.
English: What measures are being taken to ensure the safe and effective use of Glubrava?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Glubrava?
English: The usual dose of Glubrava is one tablet taken twice a day.
Croatian: Uobičajena doza lijeka Glubrava jest jedna tableta dvaput na dan.
English: What is Glubrava?
Croatian: Što je Glubrava?
English: What is the risk associated with Glubrava?
Croatian: Koji su rizici povezani s lijekom Glubrava?
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Glubrava on 11 December 2007.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Glubrava na snazi u Europskoj uniji od 11. prosinca 2007.
English: Glubrava is a medicine that is available as tablets containing two active substances, pioglitazone (15 mg) and metformin hydrochloride (850 mg).
Croatian: Glubrava je lijek koji je dostupan u obliku tableta koje sadrže dvije djelatne tvari, pioglitazon (15 mg) i metformin hidroklorid (850 mg).
English: For more information about treatment with Glubrava, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Glubrava pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svojem liječniku ili ljekarniku.
English: This is a summary of the European public assessment report (EPAR) for Glubrava.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Glubrava.
English: At the start of treatment, abdominal pain (stomach ache), diarrhoea, loss of appetite, nausea (feeling sick) and vomiting may occur.
Croatian: Na početku liječenja mogu se pojaviti abdominalna bol (bol u želucu), proljev, gubitak apetita, mučnina (osjećaj slabosti) i povraćanje.
English: Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Croatian: Pioglitazon čini stanice (masti, mišića i jetre) osjetljivijima na inzulin, što znači da tijelo u većoj mjeri koristi inzulin koji proizvodi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glubrava.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Glubrava.
English: Glubrava contains two active substances which each have a different mode of action.
Croatian: Lijek Glubrava sadrži dvije djelatne tvari, a svaka od njih djeluje na drugačiji način.
English: Why has Glubrava been approved?
Croatian: Zašto je lijek Glubrava odobren?
English: Lactic acidosis (a build-up of lactic acid in the body) is a side effect which may occur in less than 1 in 10,000 patients.
Croatian: Laktacidoza (nakupljanje mliječne kiseline u tijelu) nuspojava je koja se može javiti u manje od 1 na 10 000 bolesnika.